Preventing complications like cirrhosis and hepatocellular cancer hinges on early detection and treatment for chronic hepatitis B (CHB). An invasive, sophisticated, and costly method, liver biopsy, holds the distinction of being the gold standard for fibrosis identification. Through this study, the aim was to determine the impact of these examinations in forecasting liver fibrosis and determining subsequent treatment procedures.
Data from the Gastroenterology Department of Gaziantep University were retrospectively examined, including 1051 patients with CHB diagnosed between 2010 and 2020. The commencement of the diagnosis was marked by the determination of AAR, API, APRI, FIB-4, KING score, and FIBROQ score. A new formula, the Zeugma score, which is thought to demonstrate increased sensitivity and specificity, was determined. In light of the patients' biopsy results, the performance of noninvasive fibrosis scores was examined.
In this study, significant differences were observed in the area under the curve values, which were 0.648 for API, 0.711 for APRI, 0.716 for FIB-4, 0.723 for KING, 0.595 for FIBROQ, and 0.701 for Zeugma (p < 0.005). No statistically appreciable difference was detected for the AAR score. For the purpose of diagnosing advanced fibrosis, the KING, FIB-4, APRI, and Zeugma scores presented the most accurate results. Scores for KING, FIB-4, APRI, and Zeugma were used to predict advanced fibrosis, with respective cutoff values of 867, 094, 1624, and 963. These cutoffs achieved sensitivities of 5052%, 5677%, 5964%, and 5234% and specificities of 8726%, 7496%, 7361%, and 7811%, respectively (p<0.005). Fibrosis, an aspect of the Zeugma score, was evaluated in relation to globulin and GGT parameters within our study. Significant increases in globulin and GGT mean values were observed exclusively in the fibrosis patient cohort (p<0.05). Fibrosis exhibited a statistically significant correlation with both globulin and GGT values, with p-values less than 0.005 and correlation coefficients of 0.230 and 0.305, respectively.
The KING score stood out as the most trustworthy noninvasive approach for the identification of hepatic fibrosis in chronic HBV patients. The FIB-4, APRI, and Zeugma scores proved effective tools in the diagnosis of liver fibrosis. The AAR score's diagnostic limitations for hepatic fibrosis were highlighted by the research. PCO371 datasheet The novel noninvasive Zeugma score offers a useful and straightforward method to assess liver fibrosis in patients with chronic HBV, exhibiting superior accuracy compared to AAR, API, and FIBROQ.
Hepatic fibrosis in chronic HBV patients was most reliably detected non-invasively using the KING score. The FIB-4, APRI, and Zeugma scores proved effective indicators of liver fibrosis. It was determined that the AAR score fell short of adequately identifying hepatic fibrosis. The novel, noninvasive Zeugma score facilitates a convenient assessment of liver fibrosis in chronic HBV patients, demonstrating superior accuracy compared to AAR, API, and FIBROQ.

Hepatoportal sclerosis, an idiopathic non-cirrhotic portal hypertension (INCPH), manifests with hypersplenism, coupled with portal hypertension and splenomegaly. Amongst the various forms of liver cancer, hepatocellular carcinoma (HCC) is the most common. In exceedingly uncommon cases, non-cirrhotic portal hypertension is a contributing factor to the onset of hepatocellular carcinoma. A 36-year-old female patient presented to our hospital with the diagnosis of esophageal varices. The etiology was investigated through serological tests, all of which were negative. The levels of serum ceruloplasmin and serum immunoglobulins A, M, and G were found to be within the normal parameters. The follow-up triple-phase computer scan highlighted the presence of two hepatic lesions. Despite arterial enhancement in the lesions, no washout was noted in the venous phase. The magnetic resonance imaging scan revealed a potential for hepatocellular carcinoma (HCC) at one particular lesion. Initial application of radiofrequency ablation therapy targeted a patient exhibiting no evidence of metastatic spread. The patient's living donor liver transplant materialized within a timeframe of two months. Well-differentiated HCC and HPS, as observed in explant pathology, were determined to be the etiological factors for non-cirrhotic portal hypertension. Throughout a three-year follow-up, the patient demonstrated no relapse. Debate persists regarding the incidence of hepatocellular carcinoma (HCC) in individuals with INCPH. Even with the presence of atypical and diverse liver cells within nodular regenerative hyperplasia liver tissues, a causal relationship between hepatocellular carcinoma and nodular regenerative hyperplasia is not definitively known.

For optimal long-term results in patients who undergo liver transplantation, it's critical to prevent the reinfection with hepatitis B virus (HBV). People who receive Hepatitis B immunoglobulin (HBIG) include (i) those with existing hepatitis B disease, (ii) those exhibiting a positive hepatitis B core antibody (HBcAb) status, or (iii) recipients of hepatitis B core antibody (HBcAb)-positive organs. Nucleo(s)tide analogue (NA) monotherapy is demonstrating increasing efficacy in treating patients in this clinical setting. There's no widespread consensus regarding the ideal HBIG dosage level. Evaluating the potency of a reduced dose of HBIG (1560 international units [IU]) was the objective of this investigation to preclude HBV transmission post-liver transplant.
During the period of January 2016 to December 2020, a retrospective analysis was carried out, evaluating HBcAb-positive patients who received either HBcAb-positive or hepatitis B core antibody-negative (HBcAb-negative) organs, and also HBcAb-negative patients who received HBcAb-positive organs. Pre-LT hepatitis B virus serologies were collected. Nucleotides/nucleoside analogues (NAs) were a key component of the hepatitis B virus (HBV) prophylaxis protocol, with the possible inclusion of hepatitis B immune globulin (HBIG). The presence of HBV deoxyribonucleic acid (DNA) during the one-year post-liver transplant (LT) follow-up period signified HBV recurrence. There was no assessment of HBV surface antibody titer levels.
A total of 103 patients, with a median age of 60 years, were included in the research study. The Hepatitis C virus was determined to be the most common origin. Of the recipients, 37 lacked HBcAb, while 11 possessed HBcAb and had undetectable HBV DNA levels. They all received HBcAb-positive organs, and underwent prophylaxis with four doses of low-dose HBIG and NA. Among the recipients in our cohort, HBV recurrence was not observed at the one-year point.
A 4-day regimen of low-dose HBIG (1560 IU) appears to be effective in preventing HBV reinfection in HBcAb-positive recipients and donors, alongside NA, following liver transplantation. Subsequent trials are needed to corroborate this observation.
Recipients and donors with positive HBcAb, receiving low-dose HBIG (1560 IU) for four days and NA, demonstrate an apparent effectiveness in preventing HBV reinfection post-LT. To confirm this observation, a larger number of trials is imperative.

A wide spectrum of etiologies underlies chronic liver disease (CLD), a major contributor to global morbidity and mortality. FibroScan, the technology for liver fibrosis measurement.
Fibrosis and steatosis are tracked with the help of this. The distribution of reasons for FibroScan referrals, as observed in this single-center study, will be the subject of this review.
.
The interplay between demographic factors, FibroScan outcomes, and the underlying causes of chronic liver disease (CLD) warrants thorough investigation.
Retrospectively, we assessed the parameters of patients who were directed to our tertiary care center during the period of 2013 to 2021.
Of the 9345 patients, 4946 were male, comprising 52.93% of the total, with a median age of 48 years, ranging from 18 to 88 years. The most frequently observed indication was nonalcoholic fatty liver disease (NAFLD), accounting for 4768 (51.02%) cases. Hepatitis B accounted for 3194 cases (34.18%), ranking second in frequency. Hepatitis C, with 707 cases (7.57%), was the least common indication. Statistically controlling for age, sex, and the cause of chronic liver disease, the study revealed elevated odds of advanced liver fibrosis in patients with older age (Odds Ratio (OR)=2908; Confidence Interval (CI)=2597-3256; p<0.0001), hepatitis C (OR=2582; CI=2168-3075; p<0.0001), alcoholic liver disease (OR=2019; CI=1524-2674; p<0.0001), and autoimmune hepatitis (OR=2138; CI=1360-3660; p<0.0001), contrasting with patients with non-alcoholic fatty liver disease (NAFLD).
FibroScan was most often requested due to the presence of NAFLD.
.
The diagnosis of NAFLD was the most common determinant for FibroScan testing.

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) is expected to be substantial among kidney transplant recipients (KTRs). The present study evaluated the incidence of MAFLD in the KTR cohort, a topic untouched by prior clinical research.
Prospective consecutive recruitment yielded 52 KTRs and 53 individuals matched for age, sex, and BMI, who formed the control group. The controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) from FibroScan indicated hepatic steatosis and liver fibrosis.
A notable 18 of the KTRs (346%) displayed characteristics of metabolic syndrome. PCO371 datasheet The KTR group demonstrated a prevalence of MAFLD at 423%, and the control group exhibited a prevalence of 519% (p=0.375). The KTR and control groups exhibited no substantial disparity in CAP and LSM values (p=0.222 and p=0.119, respectively). PCO371 datasheet Among KTR patients, those with MAFLD exhibited a statistically significant correlation with increased age, BMI, waist circumference, LDL, and total cholesterol levels (p<0.0001, p=0.0011, p=0.0033, p=0.0022, and p=0.0029, respectively). Among the KTRs, multivariable analysis revealed age as the only independent variable significantly associated with MAFLD, yielding an odds ratio of 1120 (95% CI: 1039-1208).
KTRs did not exhibit a significantly elevated rate of MAFLD when compared with the normal population. Further clinical investigation with larger cohorts is necessary.